New study using the RiiQ™ to assess clinical progression of COVID-19

An exciting new study by Oxford University & Cancer Research UK has used the RiiQ™ to assess clinical progression of COVID-19:

Halford, et al. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials. 2021;22:550.